Español
Polski
English
українська
Nota: La revisión de las publicaciones abarca el período comprendido entre el 21/04/2021 y el 30/03/2022.
Siglas y abreviaturas: AR — artritis reumatoide, COVID-19 — enfermedad por coronavirus de 2019, DM — diferencia de medias, DMO — densidad mineral ósea, DXA — absorciometría con rayos X de doble energía, ESCEO — European Society for Clinical and Economic Aspects of Osteoporosis, IC — intervalo de confianza, IOF — International Osteoporosis Foundation, OIG — osteoporosis inducida por glucocorticoides
Bibliografía:
1. Kanis J.A., Norton N., Harvey N.C. y cols., SCOPE 2021: a new scorecard for osteoporosis in Europe, Arch. Osteoporos., 2021; doi: 10.1007/s11 657 020 00 871 92. Willers C., Norton N., Harvey N.C. y cols., Osteoporosis in Europe: a compendium of country specific reports, Arch. Osteoporos., 2022; doi: 10.1007/s11 657 021 00 969 8
3. Huang C.F., Shiao M.S., Mao T.Y., Retrospective analysis of the effects of non compliance with denosumab on changes in bone mineral density during the COVID 19 pandemic, Patient Prefer. Adherence, 2021: 15: 1579-1584
4. Pelin A.M., Georgescu C., Stefan S.C. y cols., Treatment strategies in osteoporosis-an analysis of practice guidelines, Progress Nutr., 2021; doi: 10.23 751/pn.v23i2.9748
5. Curtis E.M, Reginster J.Y., Al Daghri N. y cols., Management of patients at very high risk of osteoporotic fractures through sequential treatments, Aging Clin. Exp. Res., 2022; doi: 10.1007/s40 520 022 02 100 4
6. Khalid S., Pineda Moncusí M., El Hussein L. y cols., Predicting imminent fractures in patients with a recent fracture or starting oral bisphosphonate therapy: development and international validation of prognostic models, J. Bone Miner. Res., 2021; 36: 2162-2176
7. McCloskey E.V., Borgstrom F., Cooper C. y cols., Short time horizons for fracture prediction tools: time for a rethink, Osteoporosis. Int., 2021; 32: 1019-1025
8. American College of Obstetricians and Gynecologists’ Committee on Clinical Practice Guidelines – Gynecology: Prevention, screening and dignosis of osteoporosis, ACOG Clinical Practice Guideline No. 1, Obstet. Gynecol., 2021; 138: 494-506
9. Kobza A.O., Herman D., Papaioannou A. y cols., Understanding and managing corticosteroid induced osteoporosis, Open Access Rheumatology: Research and Reviews 2021: 13 177-190
10. Pereira R.M.R, Perez M.O, Paula A.P. y cols., Guidelines for the prevention and treatment of glucocorticoid induced osteoporosis: an update of Brazilian Society of Rheumatology (2020), Arch. Osteoporos., 2021; doi: 10.1007/s11 657-021-00-902-z
11. Mok C.C., Ho L.Y., Tik Leung S.M. y cols., Denosumab versus alendronate in long term glucocorticoid users: A 12 month randomized controlled trial, Bone, 2021; doi: 10.1016/j. bone.2021.115 902
12. Hu Q., Zhong X., Tian H., Liao P.: The efficacy of denosumab in patients with rheumatoid arthritis: A systematic review and pooled analysis of randomized or matched data, Front. Immunol., 2021; doi: 10.3389/fimmu.2021.799 575
13. Minisola S., Colangelo L., Pepe J. y cols., Osteomalacia and vitamin D status: a clinical update 2020, J. Bone Mineral. Res. Plus, 2021; doi: 10.1002/jbm4.10 447
